Integrate & Intensify Your Up- & Downstream Process Development & Enhance Functional Product Quality to Streamline Scale-Up & Reduce COGS
February 20 - 22 | Boston, MA
Create Qualitative, Accessible Treatments for Patients
Following Ring Therapeutics’ injection of $86.5m to enhance novel viral vector capabilities, and BMS’s viral vector facility coming online, the viral vector market is forecasted to reach $12.8bn – not only in cell and gene therapies but also viral-vector-based vaccines and immunotherapies.
With the FDA’s fast-evolving quality assessment and lack of standard guidance, and the continued challenge of viral vector recovery yield and purity, the 2nd Viral Vector Process Development & Manufacturing Summit is your must-attend meeting in 2024 to help answer your burning questions to enhance process intensification capabilities while meeting regulatory agencies’ expectations.
In collaboration with Sarepta, Ultragenyx, Affinia Therapeutics, and UCB, we will unite 80+ pioneering viral vector up- and downstream process engineers, MSAT, CMC to tackle these challenges together. This is your definitive community to seek help from industry pioneers to expedite scale-up, tech transfer, and speed-to-clinic. Join your peers to explore:
Downstream process intensification, including purification, to improve recovery and yield
Purity assessment to uphold GMP and product quality assessment
Deep dive into upstream process development and cell line in relation to your viral vectors, and assess platforming strategy
Rapid scale-up with robust analytical capabilities and improve your full:empty capsid ratio and reduce COGs
Meet and evaluate solution providers and viral vector CDMOs, including Lonza, Chromatan, Teknova, and Genezen, to forge long-term relationships, ensuring tech transfer readiness
It’s worth clearing 2 days out of your office and joining this summit to leverage novel platform technologies such as continuous processing to improve viral vector manufacturing!
World-Class Speaker Faculty Includes:
Head of Process Development & Manufacturing Innovations
Vice President - Process and Analytical Development
Associate Director Viral Production Core
Associate Director - Process Development
“The very focused nature of this meeting made it very easy to network & interact with more people. The audience was very engaged & participated in discussion which was extremely helpful.”
Vice President, Process Analytical Development, Neurogene
“Well organized event covering important topics for viral vector manufacturing and analytics. High-quality presentations and engaged audiences. The intimate room and environment made it easy to openly communicate.”
Director & Head, Viral Vector R&D, Lonza
“The conference had the perfect mix of technical content and breaks. I was able to focus on the presentations & had enough time to follow-up with speakers afterwards.”
Principal Scientist, Capsida Biotherapeutics